United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - sugammadex sodium (unii: erj6x2mxv7) (sugammadex - unii:361lpm2t56) - sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.  pediatric use information is approved for merck sharp & dohme corp., a subsidiary of merck & co. inc.’s bridion ® (sugammadex injection). however, due to merck sharp & dohme corp., a subsidiary of merck & co. inc.’s marketing exclusivity rights, this drug product is not labeled with that information. sugammadex is contraindicated in patients with known hypersensitivity to sugammadex or any of its components. hypersensitivity reactions that occurred varied from isolated skin reactions to serious systemic reactions (i.e., anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex [see warnings and precautions (5.1), adverse reactions (6)].  risk summary  there are no clinical trial data on sugammadex use in pregnant women to inform any drug-associated risks. the available data from

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - sugammadex sodium, quantity: 217.6 mg (equivalent: sugammadex, qty 200 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - sugammadex sodium, quantity: 544 mg (equivalent: sugammadex, qty 500 mg) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.

United States - English - NLM (National Library of Medicine)

patheon manufacturing services llc - sugammadex (unii: 361lpm2t56) (sugammadex sodium - unii:erj6x2mxv7) - sugammadex 500 mg in 5 ml

Malta - English - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products

Malta - English - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products

Malta - English - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products

Malta - English - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products

European Union - English - EMA (European Medicines Agency)

piramal critical care b.v. - sugammadex sodium - neuromuscular blockade - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

European Union - English - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults.for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.